(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2022 (12.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/095913 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61P 31/14* (2006.01)
A61K 31/404 (2006.01)

(21) International Application Number:
PCT/CN2021/128521

(22) International Filing Date:
03 November 2021 (03.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2020/126596
04 November 2020 (04.11.2020) CN

(71) Applicant: **JANSSEN PHARMACEUTICALS, INC.** [US/US]; 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (US).

(71) Applicant *(for SC only)*: **JOHNSON & JOHNSON (CHINA) INVESTMENT LTD.** [CN/CN]; 2101, No. 1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN).

(72) Inventors: **ZHU, Donghua**; Johnson & Johnson (China) Investment Ltd., 2101, No. 1 Building, 65 Gui Qing Road, Xuhui District, Shanghai 200233 (CN). **KIMPE, Kristof, Leonard**; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **ANDERSEN, Sune, Klint**; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **RAVELINGIEN, Matthieu, Jean, M.**; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **SOMERS, Ivan, Henri, M.**; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agent: **NTD UNIVATION INTELLECTUAL PROPERTY AGENCY LTD.**; 10th Floor, Tower C, Beijing Global Trade Center, 36 North Third Ring Road East, Dongcheng District, Beijing 100013 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: SOLID FORMULATION




FIGURE 1

(57) Abstract: The invention relates to pharmaceutical formulations comprising an active pharmaceutical ingredient; and one of or a combination of methacrylic acid copolymer, or a cellulose derivative wherein the active pharmaceutical ingredient is a dengue viral replication inhibitor. Solid dosage forms comprising said pharmaceutical formulations, processes for preparing these and their use in methods of prevention and/or treatment and/or inhibition of viral replication are also described.

WO 2022/095913 A1

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*